ArticleLife (Basel, Switzerland)2024
Assessing Type 2 Diabetes Risk in the Post-Pandemic Era: A Pharmacy-Led FINDRISC Screening Study.
Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Scoping Review on Community-based Diabetes Screening Interventions: Paving the Pathway to Early Care and Prevention of Diabetes.Current diabetes reports · 2025Article
- Bright night sleeping environment induces diabetes and impaired glucose tolerance in non-human primates.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetes mellitus (DM) is a major global health issue, with type 2 diabetes (T2D) accounting for over 90% of cases. Community pharmacies, given their accessibility, are well positioned to assist in early detection and management of T2D. This study evaluated post-pandemic T2D risk in a Portuguese population using the Finnish Diabetes Risk Score (FINDRISC) across five community pharmacies. A total of 494 participants aged 40 or older without a prior diagnosis of diabetes were assessed. The mean FINDRISC score was 12.3, and 29.8% were identified as high or very high-risk, with 8.7% referred to general practitioners for follow-up based on elevated glycated hemoglobin (HbA1c). Key risk factors include age, body mass index, waist circumference, lack of physical activity, and family history of diabetes. Lower educational levels were also associated with higher diabetes risk. Community pharmacies are shown to play an essential role in screening and educating at-risk populations, emphasizing the importance of physical activity, healthy diets, and regular monitoring. These findings reinforce the value of community pharmacists in mitigating T2D risk and enhancing public health outcomes through cost-effective, validated screening tools like FINDRISC. Finally, pre-pandemic FINDRISC studies discussed show similar results suggesting that the COVID-19 pandemic did not significantly impact the overall risk profile for T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.